Literature DB >> 22197270

The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.

K S Murnane1, H L Kimmel, K C Rice, L L Howell.   

Abstract

3,4-methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine that is widely abused as the street drug "ecstasy". Racemic MDMA (S,R(+/-)-MDMA) and its stereoisomers elicit complex spectrums of psychobiological, neurochemical, and hormonal effects. In this regard, recent findings demonstrated that S,R(+/-)-MDMA and its stereoisomer R(-)-MDMA elicit increases in striatal extracellular serotonin levels and plasma levels of the hormone prolactin in rhesus monkeys. In the present mechanistic study, we evaluated the role of the serotonin transporter and the 5-HT(2A) receptor in S,R(+/-)-MDMA- and R(-)-MDMA-elicited prolactin secretion in rhesus monkeys through concurrent microdialysis and plasma analysis determinations and drug interaction experiments. Concurrent neurochemical and hormone determinations showed a strong positive temporal correlation between serotonin release and prolactin secretion. Consistent with their distinct mechanisms of action and previous studies showing that the serotonin transporter inhibitor fluoxetine attenuates the behavioral and neurochemical effects of S,R(+/-)-MDMA, pretreatment with fluoxetine attenuated serotonin release elicited by either S,R(+/-)-MDMA or R(-)-MDMA. As hypothesized, at a dose that had no significant effects on circulating prolactin levels when administered alone, fluoxetine also attenuated prolactin secretion elicited by S,R(+/-)-MDMA. In contrast, combined pretreatment with both fluoxetine and the selective 5-HT(2A) receptor antagonist M100907 was required to attenuate prolactin secretion elicited by R(-)-MDMA, suggesting that this stereoisomer of S,R(+/-)-MDMA elicits prolactin secretion through both serotonin release and direct agonism of 5-HT(2A) receptors. Accordingly, these findings inform our understanding of the neuropharmacology of both S,R(+/-)-MDMA and R(-)-MDMA and the regulation of prolactin secretion.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22197270      PMCID: PMC3278534          DOI: 10.1016/j.yhbeh.2011.10.012

Source DB:  PubMed          Journal:  Horm Behav        ISSN: 0018-506X            Impact factor:   3.587


  43 in total

1.  Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

Authors:  G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes
Journal:  Soc Neurosci       Date:  2009       Impact factor: 2.083

2.  In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys.

Authors:  Kristin M Wilcox; Heather L Kimmel; Kimberly P Lindsey; John R Votaw; Mark M Goodman; Leonard L Howell
Journal:  Synapse       Date:  2005-12-15       Impact factor: 2.562

3.  Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate.

Authors:  B Gough; S F Ali; W Slikker; R R Holson
Journal:  Pharmacol Biochem Behav       Date:  1991-07       Impact factor: 3.533

Review 4.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

5.  The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status.

Authors:  O Spigset; T Mjorndal
Journal:  J Clin Psychopharmacol       Date:  1997-08       Impact factor: 3.153

6.  The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine.

Authors:  U V Berger; X F Gu; E C Azmitia
Journal:  Eur J Pharmacol       Date:  1992-05-14       Impact factor: 4.432

7.  Repeated adolescent MDMA ("Ecstasy") exposure in rats increases behavioral and neuroendocrine responses to a 5-HT2A/2C agonist.

Authors:  Dominik K Biezonski; Andrea B Courtemanche; Sang B Hong; Brian J Piper; Jerrold S Meyer
Journal:  Brain Res       Date:  2008-11-25       Impact factor: 3.252

Review 8.  From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions.

Authors:  Ana B F Emiliano; Julie L Fudge
Journal:  Neuropsychopharmacology       Date:  2004-05       Impact factor: 7.853

9.  Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors.

Authors:  J F Nash; B L Roth; J D Brodkin; D E Nichols; G A Gudelsky
Journal:  Neurosci Lett       Date:  1994-08-15       Impact factor: 3.046

10.  Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA.

Authors:  Marcy J Bubar; Kami M Pack; Paul S Frankel; Kathryn A Cunningham
Journal:  Psychopharmacology (Berl)       Date:  2004-04-03       Impact factor: 4.530

View more
  14 in total

Review 1.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

Review 2.  Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder.

Authors:  Kevin Sean Murnane
Journal:  Behav Pharmacol       Date:  2019-04       Impact factor: 2.293

3.  GABAA receptor positive allosteric modulators modify the abuse-related behavioral and neurochemical effects of methamphetamine in rhesus monkeys.

Authors:  Laís F Berro; Monica L Andersen; Sergio Tufik; Leonard L Howell
Journal:  Neuropharmacology       Date:  2017-05-08       Impact factor: 5.250

4.  M100907 and BD 1047 attenuate the acute toxic effects of methamphetamine.

Authors:  Azizi Ray; Clinton E Canal; J Christopher Ehlen; Kenner C Rice; Kevin Sean Murnane
Journal:  Neurotoxicology       Date:  2019-06-01       Impact factor: 4.294

5.  The acute toxic and neurotoxic effects of 3,4-methylenedioxymethamphetamine are more pronounced in adolescent than adult mice.

Authors:  Neha Milind Chitre; Monique Simone Bagwell; Kevin Sean Murnane
Journal:  Behav Brain Res       Date:  2019-12-03       Impact factor: 3.332

6.  Effects of the serotonin 2C receptor agonist WAY163909 on the abuse-related effects and mesolimbic dopamine neurochemistry induced by abused stimulants in rhesus monkeys.

Authors:  Laís F Berro; Maylen Perez Diaz; Eric Maltbie; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-06-05       Impact factor: 4.530

7.  Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Matthew B Young; Seth D Norrholm; Lara M Khoury; Tanja Jovanovic; Sheila A M Rauch; Collin M Reiff; Boadie W Dunlop; Barbara O Rothbaum; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-07-24       Impact factor: 4.530

8.  Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice.

Authors:  Aboagyewaah Oppong-Damoah; Kristen E Curry; Bruce E Blough; Kenner C Rice; Kevin S Murnane
Journal:  Psychopharmacology (Berl)       Date:  2019-07-15       Impact factor: 4.530

Review 9.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

10.  Nanoparticle encapsulation increases the brain penetrance and duration of action of intranasal oxytocin.

Authors:  Aboagyewaah Oppong-Damoah; Rokon Uz Zaman; Martin J D'Souza; Kevin Sean Murnane
Journal:  Horm Behav       Date:  2018-12-30       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.